Related Experiment Videos
Using prostate-specific antigen to eliminate unnecessary diagnostic tests: significant worldwide economic
1Michigan Prostate Institute, University of Michigan, Ann Arbor 48109, USA.
Urology
|September 1, 1995
Summary
Prostate-specific antigen (PSA) testing is a cost-effective tool for diagnosing and staging prostate cancer. Utilizing PSA can reduce the need for invasive procedures like biopsies and lymph node dissections, improving patient outcomes and lowering healthcare costs.
Area of Science:
- Urology
- Oncology
- Biomarker Research
Background:
- The 21st century necessitates cost-effective methods for diagnosing and staging malignancies.
- Traditional diagnostic and staging procedures for prostate cancer can be time-consuming, expensive, and invasive.
Purpose of the Study:
- To discuss the role of prostate-specific antigen (PSA) in the diagnosis and staging of prostate cancer.
- To review the economic benefits of utilizing PSA as a tumor marker.
Main Methods:
- PSA has replaced transrectal ultrasonography (TRUS) as a first-line diagnostic test.
- Age-specific reference ranges for serum PSA decrease the number of prostate biopsies.
- PSA aids in staging by potentially eliminating bilateral pelvic lymphadenectomy and radionuclide bone scans.
Main Results:
- PSA is now a primary diagnostic tool for early prostate cancer detection.
- Age-specific PSA ranges reduce unnecessary biopsies in older men.
- PSA can obviate the need for pelvic lymphadenectomy in 30% and bone scans in 40% of patients.
Conclusions:
- Serum PSA is a valuable tool for the cost-effective diagnosis and staging of prostate cancer.
- Proper utilization of PSA testing offers significant economic benefits in prostate cancer management.
- PSA improves efficiency in prostate cancer evaluation, reducing invasive procedures.